{"entity":{"id":"firicabtagene-autoleucel","kind":"drug","name":"Firicabtagene autoleucel","aka":["CRG-022","firi-cel"],"tldr":"Firicabtagene autoleucel is an autologous CAR T-cell therapy from CARGO Therapeutics that reached phase 2 for relapsed or refractory large B-cell lymphoma; development has stopped.","summary":"Firicabtagene autoleucel (CRG-022, firi-cel) is an autologous CAR T-cell therapy from CARGO Therapeutics, with Stanford as ran the phase 1 trial with its formulation of CRG-022. Autologous T cells engineered with a chimeric antigen receptor against CD22. Its furthest stage is phase 2, for relapsed or refractory large B-cell lymphoma. ClinicalTrials.gov registers it in one study linked below. CARGO elected to discontinue the phase 2 FIRCE-1 study on 28 January 2025 (Q1 2025 10-Q); the registry lists NCT05972720 as terminated: \"Company decision to stop trial, withdraw the IND and close down operations.\" Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"CARGO Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1966494/000095017025066940/crgx-20250331.htm"},{"label":"CARGO Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1966494/000095017025066940/crgx-20250331.htm"},{"label":"CARGO Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05972720"},{"label":"ClinicalTrials.gov: trials of CRG-022","url":"https://clinicaltrials.gov/search?intr=CRG-022"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd22"],"drugs":[],"companies":["cargo-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05972720"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CRG-022","modality":"Autologous CAR T-cell therapy","mechanism":"Autologous T cells engineered with a chimeric antigen receptor against CD22.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/firicabtagene-autoleucel/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"target":[{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/"}],"company":[{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/"}],"trial":[{"id":"nct05972720","kind":"trial","name":"A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma","route":"/trials/nct05972720/"}]}}